Year in Review: Evolving Landscape in Multiple Myeloma

Sagar Lonial, MD, FACP, discusses the encouraging activity with the BCMA-targeted agent belantamab mafodotin in multiple myeloma.

Jorge E. Cortes, MD, discusses the evolution of multiple myeloma treatment, the role of BCMA-directed therapies, and remaining questions that need to be addressed in this space

Jorge E. Cortes, MD, director of the Georgia Cancer Center at Augusta University, discusses the advantage of BCMA-targeted therapy in multiple myeloma.

Noopur Raje, MD, director, Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, and professor of medicine, Harvard Medical School, discusses data with AMG 420 in multiple myeloma.

Gareth J. Morgan, MD, PhD, a professor in the Department of Medicine and director of Multiple Myeloma Research, NYU Langone Health’s Perlmutter Cancer Center, discusses BCMA-targeted antibody-drug conjugates (ADCs) in multiple myeloma.

Noopur S. Raje, MD, discusses the preliminary data with BCMA-directed treatment strategies in multiple myeloma.

Sagar Lonial, MD, FACP, professor and chair, Department of Hematology and Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses data with belantamab mafodotin in multiple myeloma.

Gareth J. Morgan, MD, PhD, discusses ongoing research of BCMA-targeted therapies, as well as the use of venetoclax in the myeloma treatment paradigm.